433(top 1%)
papers
10.4K(top 1%)
citations
51(top 1%)
h-index
92(top 1%)
g-index
510
all documents
11.7K
doc citations
2.4K
citing journals

Top Articles

#TitleJournalYearCitations
1Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysisLancet, The2010594
2Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease PreventionCurrent Medical Research and Opinion2002510
3Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational studyLancet, The2008450
4Non-alcoholic fatty liver disease and dyslipidemia: An updateMetabolism: Clinical and Experimental2016363
5Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert PanelArchives of Medical Science2015311
6Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined HyperlipidemiaDiabetes Care2002253
7Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) studyAmerican Journal of Kidney Diseases2004224
8Leptin, cardiovascular diseases and type 2 diabetes mellitusActa Pharmacologica Sinica2018197
9Diabetes and lipid metabolismHormones2018192
10Gonadal dysfunction in systemic diseasesEuropean Journal of Endocrinology2005187
11Diabetic Nephropathy: New Risk Factors and Improvements in DiagnosisReview of Diabetic Studies2015169
12Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?Osteoporosis International2009146
13Pleiotropic Effects of Statins - Clinical EvidenceCurrent Pharmaceutical Design2009144
14Pharmacotherapy of type 2 diabetes: An updateMetabolism: Clinical and Experimental2018144
15The prevalence of the metabolic syndrome in Greece: The MetS-Greece Multicentre StudyDiabetes, Obesity and Metabolism2005134
16The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trialsEuropean Heart Journal2015126
17Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosisBlood2010124
18Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic controlDiabetes, Obesity and Metabolism2011123
19Serum Uric Acid as an Independent Predictor of Early Death After Acute StrokeCirculation Journal2007119
20Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert PanelExpert Opinion on Drug Safety2015117
21Health Benefits of the Mediterranean DietAngiology2015117
22Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronismExpert Opinion on Pharmacotherapy2008115
23Pheochromocytoma: an update on genetics and managementEndocrine-Related Cancer2007114
24The Role of Fibrate Treatment in Dyslipidemia: An OverviewCurrent Pharmaceutical Design2013104
25Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?Current Drug Targets2010100
26Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistanceJournal of Diabetes and Its Complications201897
27Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathwaysJournal of Cellular Physiology201997
28Contrast-Induced NephropathyAngiology201596
29Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) populationCurrent Medical Research and Opinion201093
30Regulation of PCSK9 by nutraceuticalsPharmacological Research201789
31Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitisMetabolism: Clinical and Experimental202088
3211beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?Metabolism: Clinical and Experimental201387
33Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneysDrug Discovery Today201987
34Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?Current Vascular Pharmacology201887
35Obesity and cardiovascular riskJournal of Hypertension201886
36Do we need to consider inflammatory markers when we treat atherosclerotic disease?Atherosclerosis200879
37Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffnessJournal of the American Society of Hypertension201475
38Cardiovascular benefits of bariatric surgery in morbidly obese patientsObesity Reviews201172
39Semaglutide as a promising antiobesity drugObesity Reviews201971
40Epicardial fat and vascular riskCurrent Opinion in Cardiology201370
41Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular RiskCurrent Vascular Pharmacology201869
42Angiotensin II reactivation and aldosterone escape phenomena in renin–angiotensin–aldosterone system blockade: is oral renin inhibition the solution?Expert Opinion on Pharmacotherapy200768
43Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk PatientsAmerican Journal of Cardiology200868
44Adrenal incidentaloma: a diagnostic challengeHormones200968
45HyperuricaemiaJournal of Cardiovascular Medicine201366
46MicroRNAs and type 2 diabetes mellitus: Molecular mechanisms and the effect of antidiabetic drug treatmentMetabolism: Clinical and Experimental201865
47Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsDrugs201864
48The pharmacokinetic considerations and adverse effects of DDP-4 inhibitorsExpert Opinion on Drug Metabolism and Toxicology201459
49The link between insulin resistance parameters and serum uric acid is mediated by adiposityAtherosclerosis201859
50Bone mineral density in men and children with haemophilia A and B: a systematic review and meta-analysisOsteoporosis International201458